Full-Time

Director of Clinical Operations

Caribou Biosciences

Caribou Biosciences

51-200 employees

Develops allogeneic CRISPR CAR-T therapies

Compensation Overview

$240k - $255k/yr

+ Bonus + Equity

Berkeley, CA, USA

Hybrid

Remote work allowed with occasional on-site visits to Berkeley, CA.

Category
Biology & Biotech (1)
Required Skills
biostatistics
Risk Management
Google Cloud Platform
Requirements
  • Bachelor’s Degree is required, in a science or a health-related field
  • A minimum of 10 years of global clinical trial management experience within the pharmaceutical or biotechnology industry
  • Early phase oncology focus is key, preferably within the hematology space
  • In-depth understanding and experience across clinical operations with a track record of success in CRO and vendor delivery oversight
  • Being a key contributor to study planning, execution, data cleaning, database locking, study report generation and regulatory inspection
  • Experience with developing protocols, SOPs, Clinical Study Reports, INDs, NDAs, as well as other clinical, regulatory, and safety documents preferred
  • Ability to lead cross functional study teams in a dynamic, evolving organization
  • Excellent communication and interpersonal skills, with the ability to lead and motivate teams and collaborate effectively across functions (internally and externally)
  • Ability to travel up to 20% based on business needs
Responsibilities
  • Provide strategic operational leadership and oversight for a key clinical program, ensuring alignment with clinical development objectives and corporate goals
  • Oversee CROs and vendors, leading governance and partnering closely to ensure accountability for delivery of operational activities, timelines, quality, and budget, and driving proactive risk management and mitigation across the study
  • Lead study-specific and cross-functional meetings, driving clear decisions, accountability, and timely issue resolution
  • Collaborate cross-functionally (Clinical, Regulatory, Translational, Data Management, Biostatistics) to ensure integrated and efficient study execution
  • Oversee study progress and performance using key metrics (e.g., enrollment, eligibility, data quality, primary endpoints), ensuring transparent communication and a solution-oriented approach
  • Proactively identify, assess, and manage study and program-level risks, including mitigation planning and escalation of critical issues
  • Ensure data quality, integrity, and completeness to support analyses, regulatory submissions, and program decision-making
  • Establish and oversee vendor governance, including performance management, SOW/budget review, and financial tracking (forecasts, accruals)
  • Ensure inspection readiness, including TMF quality, audit preparedness, and compliance with GCP and internal SOPs
  • Build and maintain strong relationships with investigators, study staff, and external partners, and represent Clinical Operations in internal governance and external interactions
Desired Qualifications
  • Prior experience in the CAR-T space, with a specific focus in hematology
  • An emphasis on inspection readiness for Clinical Operations
  • Ease and confidence in being Investigator and site-facing

Caribou Biosciences develops allogeneic CAR-T cell therapies using a CRISPR-based chRDNA platform (Cas9 and Cas12a) to create precise genome edits. Its lead approach centers on off-the-shelf, armored CAR-T cells designed to persist longer and resist exhaustion, including PD-1 knockout, enabling rapid access for patients. The company advances wholly-owned programs and collaborates with pharma partners, such as AbbVie, to push its therapies through clinical development. Its goal is to bring regulated, off-the-shelf CAR-T therapies to patients with hematologic cancers and autoimmune diseases and to reach commercialization, supported by funding through at least 2027.

Company Size

51-200

Company Stage

IPO

Headquarters

Berkeley, California

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • CB-011's 92% overall response rate supports expansion in relapsed or refractory multiple myeloma.
  • FDA alignment on ANTLER-3 gives vispa-cel a clear phase 3 path in LBCL.
  • Caribou's January 2025 CFO and CMO appointments strengthen late-stage execution and financing.

What critics are saying

  • CB-010 remains the only near-term value driver; one weak readout can crush the stock.
  • Allogeneic CAR-T faces rejection, persistence, and manufacturing consistency problems Caribou still has not solved.
  • CB-012 targets AML, where durable allogeneic cell-therapy success remains unproven and partnering value stays weak.

What makes Caribou Biosciences unique

  • Caribou's chRDNA platform enables precise Cas9 and Cas12a edits for allogeneic CAR-T.
  • CB-010 pairs TRAC knockout, CD19 insertion, and PD-1 deletion in one product.
  • CB-011 uses B2M-HLA-E immune cloaking to blunt T-cell and NK-cell rejection.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Caribou Biosciences who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Tuition Reimbursement

Generous paid vacation time

Comprehensive compensation package

ESPP

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

-4%

2 year growth

8%
TipRanks
Jan 2nd, 2025
Caribou Biosciences Appoints New CFO Amid Clinical Advancements

Caribou Biosciences announced the appointment of Sri Ryali as Chief Financial Officer, effective January 2, 2025.

TechBullion
Sep 10th, 2024
Vir Biotechnology Names Jason O'Byrne as Chief Financial Officer

Mr. O'Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO, leading the finance, investor relations, corporate communications, IT, procurement, and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease.

Stock Titan
Aug 12th, 2024
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

Caribou Biosciences (CRBU) has appointed Dr. Tina Albertson as its new Chief Medical Officer.

Endpoints News
Jul 17th, 2024
Caribou to slash preclinical allogeneic CAR-NK work, lay off 12% of staff

Caribou Biosciences is cutting its CAR-NK research and laying off 21 employees, or 12% of its staff, the company announced Tuesday.

Stock Titan
Jul 9th, 2024
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

Caribou Biosciences announces appointment of Terri Laufer, MD, to its scientific advisory board.